Stefan Walzer

1.5k total citations
99 papers, 901 citations indexed

About

Stefan Walzer is a scholar working on Pulmonary and Respiratory Medicine, Economics and Econometrics and Oncology. According to data from OpenAlex, Stefan Walzer has authored 99 papers receiving a total of 901 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 27 papers in Economics and Econometrics and 21 papers in Oncology. Recurrent topics in Stefan Walzer's work include Lung Cancer Treatments and Mutations (22 papers), Health Systems, Economic Evaluations, Quality of Life (17 papers) and Economic and Financial Impacts of Cancer (13 papers). Stefan Walzer is often cited by papers focused on Lung Cancer Treatments and Mutations (22 papers), Health Systems, Economic Evaluations, Quality of Life (17 papers) and Economic and Financial Impacts of Cancer (13 papers). Stefan Walzer collaborates with scholars based in Germany, Switzerland and United States. Stefan Walzer's co-authors include Mark Nuijten, C. Chouaïd, A. Vergnenègre, Suela Sulo, Philipp Schüetz, Francesco Grossi, Javier de Castro, Bernard Escudier, Helge Bischoff and Ernst Eckehardt Müller and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Diabetes Care.

In The Last Decade

Stefan Walzer

90 papers receiving 877 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stefan Walzer Germany 16 233 232 210 149 143 99 901
John Simes Australia 11 160 0.7× 111 0.5× 179 0.9× 110 0.7× 149 1.0× 30 1.2k
Michelle Gleeson United States 19 77 0.3× 131 0.6× 209 1.0× 81 0.5× 24 0.2× 42 1.3k
Eugene Lin United States 18 151 0.6× 128 0.6× 226 1.1× 61 0.4× 18 0.1× 61 909
Domenico Gabrielli Italy 17 182 0.8× 80 0.3× 58 0.3× 128 0.9× 31 0.2× 176 1.2k
Joanna Lis Poland 12 59 0.3× 278 1.2× 78 0.4× 97 0.7× 39 0.3× 54 904
William C. Nugent United States 20 270 1.2× 122 0.5× 162 0.8× 64 0.4× 27 0.2× 49 1.5k
Ying Zheng China 16 71 0.3× 46 0.2× 50 0.2× 65 0.4× 47 0.3× 70 770
Carlos Aguíar Portugal 18 113 0.5× 177 0.8× 43 0.2× 139 0.9× 32 0.2× 120 1.5k
Lisa Vandermeer Canada 18 234 1.0× 92 0.4× 572 2.7× 23 0.2× 148 1.0× 108 1.1k
Aaron B. Cohen United States 14 121 0.5× 65 0.3× 154 0.7× 30 0.2× 44 0.3× 52 645

Countries citing papers authored by Stefan Walzer

Since Specialization
Citations

This map shows the geographic impact of Stefan Walzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Walzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Walzer more than expected).

Fields of papers citing papers by Stefan Walzer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Walzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Walzer. The network helps show where Stefan Walzer may publish in the future.

Co-authorship network of co-authors of Stefan Walzer

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan Walzer. A scholar is included among the top collaborators of Stefan Walzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan Walzer. Stefan Walzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schüetz, Philipp, Suela Sulo, Stefan Walzer, et al.. (2021). Cost savings associated with nutritional support in medical inpatients: an economic model based on data from a systematic review of randomised trials. BMJ Open. 11(7). e046402–e046402. 36 indexed citations
2.
Foxon, G., et al.. (2020). PMD17 Comparison of Market Access Routes of Digital Health Applications in France, Germany and the UK. Value in Health. 23. S579–S579. 1 indexed citations
3.
Walzer, Stefan, et al.. (2019). PBI38 INNOVATIVE ATMPS: MARKET ACCESS AND REIMBURSEMENT DECISIONS IN THE EU5: AVAILABILITY OR NOT, THAT IS THE QUESTION.... Value in Health. 22. S424–S424. 2 indexed citations
4.
Walzer, Stefan, et al.. (2019). PRO72 MARKET ACCESS, PRICING AND REIMBURSEMENT PROCESSES FOR ORPHAN DRUGS IN THE EU-5 COUNTRIES: A COMPARATIVE ASSESSMENT. Value in Health. 22. S854–S854. 1 indexed citations
5.
Schüetz, Philipp, Suela Sulo, Stefan Walzer, et al.. (2019). PAM3 INDIVIDUALIZED NUTRITIONAL SUPPORT IN MEDICAL INPATIENTS RESULTS IN COST SAVINGS: ECONOMIC EVALUATION OF THE EFFORT TRIAL. Value in Health. 22. S415–S415. 1 indexed citations
6.
Miesbach, Wolfgang, Jan Menne, Martin Bommer, et al.. (2019). Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study. Orphanet Journal of Rare Diseases. 14(1). 260–260. 27 indexed citations
7.
8.
Walzer, Stefan, et al.. (2015). Are Vaccinations Really Different to Pharmaceuticals With Respect to Market Access In Germany?. Value in Health. 18(7). A548–A549. 1 indexed citations
9.
10.
Walzer, Stefan, et al.. (2015). Which Risk Share Agreements are Available and are Those Applied In Global Reimbursement Decisions?. Value in Health. 18(7). A568–A568. 2 indexed citations
11.
Frohlich, Norman, et al.. (2015). A Systematic Comparision of Iqwig Recommendations and G-Ba Decisions In The Amnog Process In Germany. Value in Health. 18(7). A547–A548. 1 indexed citations
12.
13.
14.
Walzer, Stefan, et al.. (2013). Clinical and Health Economic Evidence Requirements for Obtaining Health Insurance Coverage for Innovative Medical Devices in Germany. Value in Health. 16(7). A474–A474. 4 indexed citations
15.
Walzer, Stefan, et al.. (2013). The Potential Cost-Effectiveness of Obinutuzumab (Ga101) in Combination with Chlorambucil in Chronic Lymphocytic Leukemia. Value in Health. 16(7). A412–A412. 3 indexed citations
16.
17.
Nuijten, Mark, Javier de Castro, A. Vergnenègre, et al.. (2011). An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer. Current Medical Research and Opinion. 27(11). 2193–2201. 3 indexed citations
18.
Nuijten, Mark, Javier de Castro, C. Chouaïd, et al.. (2011). A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer. Lung Cancer. 76(3). 465–471. 15 indexed citations
19.
Palmer, Andrew, Valentine Wn, P McEwan, et al.. (2007). 'Computer modeling of diabetes and its complications: A report on the Fourth Mount Hood Challenge Meeting'. Diabetes Care. 30(6). 1638–1646. 178 indexed citations
20.
Hitchcock, William I., et al.. (2007). Caregiver preferences for pediatric asthma treatment delivery systems. Advances in Therapy. 24(6). 1240–1253. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John Simes Breakdown of academic impact, for papers by Michelle Gleeson Breakdown of academic impact, for papers by Eugene Lin Breakdown of academic impact, for papers by Domenico Gabrielli Breakdown of academic impact, for papers by Joanna Lis Breakdown of academic impact, for papers by William C. Nugent Breakdown of academic impact, for papers by Ying Zheng Breakdown of academic impact, for papers by Carlos Aguíar Breakdown of academic impact, for papers by Lisa Vandermeer Breakdown of academic impact, for papers by Aaron B. Cohen
Rankless by CCL
2026